Skip to main content

Month: April 2025

First National Corporation Reports First Quarter 2025 Financial Results

STRASBURG, Va., April 30, 2025 (GLOBE NEWSWIRE) — First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported earnings for the quarter ending March 31, 2025 of $1.52 million and basic and diluted earnings per common share of $0.18. Excluding acquisition-related items adjusted earnings(1) (non-GAAP) for the first quarter of 2025 were $3.1 million and adjusted basic and diluted earnings(1) per common share was $0.35. “We completed the Touchstone system conversion during the first quarter of 2025 and are looking forward to building upon this transformational acquisition.  Earnings were impacted short-term in the first quarter from merger related expenses as well as operating on two different systems until late February.  Going forward we expect to return...

Continue reading

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Conference call to be held Monday, May 5, 2025, at 8:30 AM ET NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay...

Continue reading

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM (ET) on Wednesday, May 7th, 2025. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development...

Continue reading

DT Midstream Reports Strong First Quarter 2025 Results

DETROIT, April 30, 2025 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) today announced first quarter 2025 reported net income of $108 million, or $1.06 per diluted share. For the first quarter of 2025, Operating Earnings were $108 million, or $1.06 per diluted share. Adjusted EBITDA for the quarter was $280 million.   Reconciliations of Operating Earnings and Adjusted EBITDA (non-GAAP measures) to reported net income are included at the end of this news release. The company also announced that the DT Midstream Board of Directors declared a $0.82 per share dividend on its common stock payable July 15, 2025 to stockholders of record at the close of business June 16, 2025. “Our first quarter results give us a great start to the year,” said David Slater, President and CEO. “I am especially pleased with the progress our team has...

Continue reading

VCI Global’s High-Growth Fintech Startup Credilab Secures Strategic Investment from Dubai Fund

US$1 Million Funding to Accelerate Credilab’s Push Toward Unicorn Status and Regional Market Leadership KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that its fintech subsidiary, Credilab Sdn Bhd (“Credilab”), a fast-scaling digital lending platform, has secured a strategic investment worth US$1 million from Triple Helix Capital Ltd (“Triple Helix”), a leading Dubai-based private investment fund. Credilab is focused on promoting financial inclusion by providing same-day loan disbursements to the microfinance and small and medium-sized enterprise (SME) segments that have historically been underserved by traditional banks. Operating under a licensed money lending business approved by the Ministry of Housing and Local Government in Malaysia,...

Continue reading

UAB “Atsinaujinančios energetikos investicijos” publishes its factsheet for the first quarter of 2025

UAB “Atsinaujinančios energetikos investicijos” (the Company) publishes its factsheet, providing information about the Company’s investment portfolio, key events, business strategy, operating segments, and financial indicators as of 31 March 2025. 2025 Q1 KEY EVENTSTotal aggregated 2025 YTD Revenue and YTD EBITDA amounted to 2,437 kEUR and 1,226 kEUR, respectively. Following the issuance of its audited financial statements for 2024, UAB “Atsinaujinančios Energetikos Investicijos” has retrospectively adjusted its net asset value (NAV) and share price as at 31 December 2024 and 31 March 2025, due to discrepancies identified in the fair value measurement of investment assets.Solar development in Poland:The construction of 67.8 MW total capacity PV Energy Projects sp. z. o.o. portfolio nears...

Continue reading

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson’s Disease and Related Disorders, being held May 7th-10th in New York City, NY. Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+ Presenter: Joanne Taylor, Ph.D., Senior Vice President of Research, Gain Therapeutics Session: Oral Poster...

Continue reading

Charging Robotics Installs Wireless EV Charging System in Automatic Parking Facility

Pioneering seamless EV charging experience for robotic parking systems Tel Aviv, Israel, April 30, 2025 (GLOBE NEWSWIRE) — Charging Robotics Inc. (OTC: CHEV), a leading innovator in wireless electric vehicle (EV) charging solutions, announces that it has installed a system for wireless charging of electric vehicles with a leading supplier of robotic parking facilities. Following the installation, the ability of the system to transfer power wirelessly was demonstrated. Eventually, the system is intended to be used for charging EVs while reporting charge data to the cloud and managing the charging process based on available electricity and customer needs. This installation marks significant progress in addressing the challenges of EV charging in robotic facilities, where traditional plug-in methods are impractical. The system enables...

Continue reading

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

HighlightsReported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting ATH434-202 open-label trial in advanced MSA completed in March 2025 Cash balance on 31 March 2025 of A$17.96M with an additional A$27.1M raised subsequent to the end of the quarterMELBOURNE, Australia and SAN FRANCISCO, April 30, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2025...

Continue reading

Jeffs’ Brands Enters Into a Definitive Agreement to Sell Key U.S. Assets to a Canadian Public Company for an Approximate Valuation of $11.8 Million

The transaction includes the acquisition of Jeffs’ Brands’ wholly-owned subsidiary, Smart Repair Pro, and its approximately 49.1% ownership interest in SciSparc Nutraceutical Inc. by a Canadian public company in exchange for an up to 90% equity interest (on a fully diluted basis) in such company Tel Aviv, Israel, April 30, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that it has entered into a definitive agreement (“the Agreement”) with Plantify Foods, Inc. (TSXV: PTFY)  a Canadian public company (the “Acquiror”) to sell its wholly-owned subsidiary, Smart Repair Pro, which operates Jeffs’ Brands’ stores on the Amazon U.S. Marketplace and owns Pure NJ Logistics LLC, and its approximately 49.1%...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.